These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 18667360)

  • 21. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
    Delrieu J; Ousset PJ; Caillaud C; Vellas B
    J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.
    Levites Y; Jansen K; Smithson LA; Dakin R; Holloway VM; Das P; Golde TE
    J Neurosci; 2006 Nov; 26(46):11923-8. PubMed ID: 17108166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy against amyloid pathology in Alzheimer's disease.
    Galimberti D; Ghezzi L; Scarpini E
    J Neurol Sci; 2013 Oct; 333(1-2):50-4. PubMed ID: 23299047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Aβ3-10-KLH vaccine reduced Alzheimer's disease-like pathology and had a sustained effect in Tg-APPswe/PSEN1dE9 mice.
    Meng Y; Ding L; Zhang HY; Yin WC; Yan Y; Cao YP
    Brain Res; 2017 Oct; 1673():72-77. PubMed ID: 28779977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination as a therapeutic approach to Alzheimer's disease.
    Wisniewski T; Boutajangout A
    Mt Sinai J Med; 2010; 77(1):17-31. PubMed ID: 20101719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Active immunotherapy facilitates Aβ plaque removal following through microglial activation without obvious T cells infiltrating the CNS.
    Sha S; Xing XN; Cao YP
    J Neuroimmunol; 2014 Sep; 274(1-2):62-70. PubMed ID: 25087756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer.
    Perche F; Uchida S; Akiba H; Lin CY; Ikegami M; Dirisala A; Nakashima T; Itaka K; Tsumoto K; Kataoka K
    Curr Alzheimer Res; 2017; 14(3):295-302. PubMed ID: 27829339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA vaccine therapy for Alzheimer's disease: present status and future direction.
    Okura Y; Matsumoto Y
    Rejuvenation Res; 2008 Apr; 11(2):301-8. PubMed ID: 18442321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
    Boche D; Denham N; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. beta-peptide immunization: a possible new treatment for Alzheimer disease.
    Schenk DB; Seubert P; Lieberburg I; Wallace J
    Arch Neurol; 2000 Jul; 57(7):934-6. PubMed ID: 10891974
    [No Abstract]   [Full Text] [Related]  

  • 36. Vaccines for Alzheimer's disease: how close are we?
    Janus C
    CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
    Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
    J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Aβ42 gene vaccine for prevention and treatment of Alzheimer's disease].
    Rosenberg RN
    Rinsho Shinkeigaku; 2010 Nov; 50(11):838. PubMed ID: 21921464
    [No Abstract]   [Full Text] [Related]  

  • 39. Design and development of non-fibrillar amyloid beta as a potential Alzheimer vaccine.
    Subramanian S; Bandopadhyay D; Mishra PK; Mathew M; John M
    Biochem Biophys Res Commun; 2010 Apr; 394(2):393-7. PubMed ID: 20214884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle.
    Vasilevko V; Head E
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):98-113. PubMed ID: 19355931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.